Aim: Attenuated psychotic symptoms (APSs) have been the primary emphasis in youth at clinical high risk (CHR) for psychosis for assessing symptomology and determining subsequent transition to a psychotic disorder. Previous reviews primarily focused on the efficacy of cognitive behavioural therapy (CBT) on APS; however, a comprehensive assessment of other interventions to date is lacking. Therefore, we conducted a systematic review and meta-analysis of all intervention studies examining APS in CHR youth.
| INTRODUCTION
Attenuated psychotic symptoms (APSs) have been the primary emphasis in youth at clinical high risk (CHR) of psychosis in terms of assessing current symptomology and determining criteria for being at CHR and subsequent transition to full-blown psychosis Fusar-Poli & Van Os, 2013; McGlashan, Walsh, & Woods, 2010) . APSs are often assessed by measures such as the comprehensive assessment of at-risk mental state (CAARMS) (Yung, Yuen, et al., 2005) or the Structured Interview of Psychosis-Risk Syndromes (McGlashan et al., 2010) . APSs typically include unusual thought content, suspiciousness, grandiosity, perceptual abnormalities and disorganized communication.
Both severities of APS and unusual thought content, disorganized communication and suspiciousness have been shown to be predictive of transition to psychosis Cornblatt et al., 2015; , thus examining the impact of interventions on APS may help inform clinical guidelines and future trials. Interestingly, most treatment studies in CHR samples have focused primarily on diminishing transition rates to a psychotic disorder with the mean reduction of APS usually as a secondary aim.
To date, only 2 traditional pairwise meta-analyses have examined the effects of interventions on APS in CHR youth. Both reviews primarily focused on the efficacy of cognitive behavioural therapies (CBTs) and found that CBT had a small effect on the reduction of APS shown in Appendix S2. Each reviewer (P.T. and M.F.) autonomously completed title and abstract screening, and the full text of any study considered appropriate according to the selection criteria was retrieved for a comprehensive review. In addition, a Scopus (https://www.scopus.com) search was conducted using the key words "psychosis risk" and "treatment" and both the Clinicaltrials.gov registry and The International Clinical Trials Registry Platform (http://apps.who.int/trialsearch/) were searched using the terms "psychosis" and "risk". Finally, reference lists of included full-text articles were hand searched for relevant citations.
| Study selection
Two reviewers (P.T. and M.F.) independently assessed the full text of each relevant study for inclusion. Studies that met the following eligibility criteria were selected: (1) studies including participants at risk of psychosis meeting criteria for at-risk mental state, attenuated psychotic symptom syndrome or schizotypy; (2) studies including non-randomized observational studies and RCTs; (3) studies reporting follow-up APS scores using either the scale for the assessment of positive symptoms (SAPSs) (Andreasen, 1984) , brief psychiatric rating scale (BPRS) (Overall & Gorham, 1962) , the positive and negative syndrome scale (PANSS) (Kay, Flszbein, & Opfer, 1987) , the scale of prodromal symptoms (SOPSs) (Miller et al., 2003) or the CAARMS (Yung, Yung, et al., 2005) and (4) studies reporting a mean age between 12 and 30. Studies were not excluded based on languages. Case reports, review articles, editorials and studies that did not employ an intervention were excluded. Differences were resolved by a third co-author (D.D. or J.A.).
| Data extraction
Two co-authors extracted all data in duplicate (P.T. and M.F.) and a third (D.D.) verified it. Extracted data included study characteristics (author, publication year, country, study design, CHR sample size and APS scales), patient characteristics (mean AE SD age, number of/percent male) and treatment characteristics (intervention, control, duration, endpoint). The following clinical outcome data were extracted from RCTs: (1) mean AE SD APS at follow-up, (2) mean AE SD APS changes from baseline scores to follow-up scores and (3) sample size per treatment group. If articles only provided SE or confidence intervals, a SD was obtained using the Cochrane Handbook methods (Higgins & Green, 2011) . We obtained additional data by contacting corresponding authors, obtaining follow-up or review articles, and extracting data from graphs using GraphClick software in duplicate (Boyle, Samaha, Rodewald, & Hoffmann, 2013) .
For randomized studies, risk of bias was evaluated using the Cochrane Collaboration's tool for assessing risk of bias (Higgins & Green, 2011 ). For non-randomized studies, the Risk-Of-Bias In Non-randomized Studies of Interventions (ROBINS-I) was utilized to appraise quality of evidence (Sterne et al., 2016) . In the NMA, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence associated with the results in the NMA at each time point (Puhan et al., 2014) .
| Data synthesis and analysis
Due to the differences in scales used to assess APS, the principal summary measures used across the majority of meta-analyses (ie, pairwise and NMAs) were effect sizes calculated as Hedges g. Hedges g was reported as the standardized mean difference (SMD) of APS scores at follow-up (Higgins, Green, & Scholten, 2008) . However, in pairwise analysis, if APSs were rated on the same scale the pooled mean difference (MD) was reported instead of the SMD. D-serine and glycine (herein: NMDAR modulators) are both amino acids that serve as neuromodulators that act as coagonist on the NMDAR with glutamate (Javitt & Zukin, 1991; Woods et al., 2013) , therefore, we combined both treatments in the pairwise and the NMA. Enhanced care, treatment as usual, community care, monitoring and needs focused interventions were coalesced as needs-based interventions in metaanalyses due to similarities in design. Due to expected differences between studies due to study design, dose, CHR criteria and the idiosyncratic treatment strategies, all results were combined using random-effects models. Only RCTs were included in both pairwise and NMA. The kappa statistic was used to determine inter-rater reliability for title and abstract screening. All SMDs (effect sizes) with a P < .05 were considered significant and as a typical guide SMDs of 0.2 represented a small effect, 0.5 a medium effect and 0.8 a large effect (Cohen, 1988) .
For the primary analysis, direct treatment effects on APS from interventions were combined using a pairwise random-effects model by DerSimonian & Laird, 1986 . APS was stratified by available time points (eg, 6, 12 and 18 months). Thus, the likelihood of a reduction in APS in CHR youth who received a similar intervention was compared to a control intervention. Direct treatment comparisons and risk of bias were analysed using Review Manager 5 (Collaboration, 2011).
Statistical heterogeneity was calculated using the I 2 statistic with an I 2 ≥ 50% indicating substantial heterogeneity and an I 2 ≥ 75% indicating considerable heterogeneity with a P < .05 considered significant.
For the secondary analysis, treatment effects between intervention arms in RCTs were evaluated using a random-effects multivariate NMA assuming consistency and a common heterogeneity across all comparisons in the network using the generic inverse-variance method (Caldwell, Ades, & Higgins, 2005; . We opted for a random effects multivariate NMA as described by White, 2011 and Higgins et al., 2012 because it can handle more than 2 arms in one RCT and properly accounts for correlations between effect sizes from multi-arms in RCTs. Arms in RCTs that were observational in nature (eg, monitoring) was excluded from the NMA and studies including additional participants other than CHR were excluded from the NMA (eg, schizotypy). The formulae for Hedges' g detailed by White and Thomas 2005 were used to calculate the SMD for the NMA, which is considered as an unbiased estimator and involves corrections for small numbers of degrees of freedom. APS was stratified by available time points (ie, 6 and 12 months). Transitivity is an important assumption in an NMA, which assumes that comparisons in the network model are consistent (Cipriani, Higgins, Geddes, & Salanti, 2013; Jansen & Naci, 2013; Salanti, 2012) . Therefore, both a global test for inconsistency and inconsistency plots assuming loop-specific heterogeneity were produced to determine if inconsistency existed in the NMA (Chaimani, Higgins, Mavridis, Spyridonos, & Salanti, 2013; Song, Altman, Glenny, & Deeks, 2003; Veroniki, Vasiliadis, Higgins, & Salanti, 2013) . In addition, baseline characteristics (age, CHR criteria, percent male) that might modify the treatment effect were restricted using an a priori inclusion criteria to prevent inconsistencies from being introduced into the model. Surface under the cumulative ranking curve (SUCRA) plots were inspected to establish the most effective interventions compared to a better hypothetical treatment, the quicker the curve advances to one, the more probable it will be more effective (Chaimani et al., 2013; Salanti, 2012) . Network comparison-adjusted funnel plots (Chaimani et al., 2013) were used to evaluate publication bias by arrangement of interventions as active treatment vs controls.
Data in the NMA were analysed using Stata, version 13.1 (StataCorp LP, College Station, TX, USA). The graphical toolset in Stata called "networkplot" was utilized to generate graphical illustrations of the network evidence (Chaimani et al., 2013) .
3 | RESULTS
| Search yield
The search produced 3164 citations after duplicates; 2995 citations were excluded after reviewing title and abstract. Study eligibility agreement between reviewers for abstract and title screening was high (κ = 0.86). A total of 170 articles were retrieved for full-text review. Of these, 41 primary studies were eligible for inclusion in our systematic review, 17 were included in pairwise meta-analyses and 13 were included in the NMA (see Figure 1 for reasons for exclusion).
| Study and participant characteristics
Characteristics of the 41 studies included in the systematic review are outlined in Table 1 The number of CHR participants ranged from 6 to 304, for a total of 3146 CHR participants. The mean age was 19.6 years (SD = 2.98) and 1680 (53.4%) were male (range = 28-75%).
| Features of treatment interventions and controls
The mean treatment duration was 30.0 weeks (range = 4-104 weeks.).
Interventions included: CRT (N = 6) (Choi et al., 2016; Hooker et al., 2014; Loewy et al., 2016; Piskulic, Barbato, & Addington, 2012; Rauchensteiner et al., 2011; Urben, Pihet, Jaugey, Halfon, & Holzer, 2012) , family-based treatments (N = 5) (Grano et al., 2016; Landa et al., 2016; McFarlane et al., 2015; Miklowitz Dj et al., 2014; O'Brien et al., 2007) , CBT (N = 6) (Addington et al., 2011; Kim et al., 2011; Morrison Ap et al., 2004; Morrison et al., 2012; Stain et al., 2016; van der Gaag et al., 2012) , aripiprazole (N = 3) (Kobayashi et al., 2009; Liu et al., 2013; Woods et al., 2007) , NMDAR modulators (N = 3) (Kantrowitz et al., 2016; Woods et al., 2013) , omega-3 (N = 3) (Amminger et al., 2010; Cadenhead et al., 2017; McGorry et al., 2017) , integrated psy- (Berger et al., 2012) , ziprasidone (N = 1) , perospirone (N = 1) (Tsujino et al., 2013) , second generation anti-psychotics (N = 1) (Cornblatt et al., 2007) , anti-psychotics not specified (N = 3) (Morita et al., 2014; Shim et al., 2008; Walker et al., 2009 ) and heart rate variability biofeedback training ( Thirteen studies did not use a control group.
| Risk-of-bias assessment
Quality assessment of RCTs (N = 23) is reported in Figure 2 . All RCTs had a low risk of bias for random sequence generation (N = 23). RCTs had low risk of bias for allocation concealment (56%) and selective reporting (75%). Studies had a higher risk of bias for attrition bias (N = 9) and other biases such as pharmaceutical funding (N = 6). Blinding of participants and personnel had the highest risk of bias (N = 10).
Quality assessment of observational studies using ROBINS-I and the quality of the NMA using GRADE are reported in Appendix S3.
| Network pattern and network plot
The network formed complex star-shaped network plots at both 6 and 12 months due to having many competing interventions. In addition, the network plots had some sparse connections (eg, integrated psychological therapy and family therapy). Placebo and needsbased interventions were the most common comparators (Figure 3 ).
| Consistency and publication bias
Visual inspection of the comparison-adjusted funnel plots at 6-and 12-month follow-up for symmetry demonstrated the absence of small study effects with most observations falling on the null line (Appendix S4). Global tests of inconsistency and inconsistency plots found no statistically significant evidence of inconsistency in the NMA (Appendix S4).
| Primary and secondary outcomes of metaanalyses 3.7.1 | Psychosocial interventions
In the pairwise analyses, CBT interventions were not associated with a significant reduction in APS compared to controls at 6 and 12 months (SMD, −0.08; 95% CI, −0.25-0.10; I 2 = 0%; P = .37, 5 studies, N = 507 vs SMD, −0.15; 95% CI, −0.330.02; I 2 = 0%; P = .09, 6 studies, N = 500; Appendix S5). Neither was CBT associated with a reduction at 24-month follow-up (SMD, −0.19; 95% CI, −0.45 to 0.06; I 2 = 0%; P =.14, 3 studies, N = 233) In the 6 and 12-month NMA, CBT interventions were not significantly more effective at reducing APS compared to any other intervention (Figure 4) . At 12 months, SUCRA plots of the absolute effects and rank test among the 7 treatments indicated that CBT ranked higher than the other 6 treatments but this is in the context of no statistically supported efficacy compared to other interventions (see Appendix S4).
[Correction added on 4 June 2018, after first online publication:
Some parts of the above paragraph have been corrected.]
In the NMA, family therapy was not significantly more effective at reducing APS compared to all other interventions at 6 months. At 6 months, SUCRA plots of the absolute effects and rank test among the 6 treatments indicated that family therapy ranked higher than the other 5 treatments but this is in the context of no statistically supported efficacy compared to other interventions (see Appendix S4). In the NMA, IPT was not significantly more effective at reducing APS compared to any other intervention at 12 months.
| Anti-psychotics
In the pairwise analyses, risperidone plus CBT interventions were not associated with a significant reduction in APS at 6-or 12-month follow-up (MD, 0.39; 95% CI, −0.93 to 1.71; I 2 = 46%; P = .56, 2 studies, N = 146 vs MD, 0.19; 95% CI, −0.92 to 1.31; I 2 = 0%; P = .73, 2 studies, N = 110; Appendix S5). In the 6-and 12-month NMA, Abbreviations: APS, attenuated psychotic syndrome; ARMS, at-risk mental state; BPRS, brief psychiatric rating scale; CAPE, community assessment of psychiatric experiences; CAARMSs, comprehensive assessment of at-risk mental states; CBCM, cognitive-behavioural case management; CBT, cognitive behavioural therapy; COPS, criteria for prodromal symptoms; CRT, cognitive remediation therapy; DHA, docosahexaenoic acid; DSM-IV, diagnostic and statistical manual for mental disorders, 4th edition; EPA, eicosapentaenoic acid; FACT, family-aided assertive community treatment; FCTM, family-and community-oriented integrative treatment model; FFT, family focused therapy; HRV, hearth rate variability; ICD, International IPT, integrated psychological therapy; NFI, needs focused intervention; NR, not reported; PANSS, positive and negative syndrome scale; PMFG, psychoeducational multi-family group; PUFA, polyunsaturated fatty acid; RDD, regression discontinuity design; RCT, randomized controlled trial; SAPSs, scale for the assessment of positive symptoms; SOPSs, scale of prodromal symptoms; SSRIs, selective serotonin reuptake inhibitors; TAU, treatment as usual; USA, United States of America. 
| Omega-3
In the pairwise analyses, omega-3 interventions were not associated with a significant reduction in APS at 3-, 6-or 12-month follow-up compared to placebo (SMD, −0.40; 95% CI, −1.13 to 0.33; I 2 = 81%; P = .28, 2 studies, N = 162) vs SMD, −0.34; 95% CI, −0.97 to 0.29; I 2 = 87%; P = .30, 3 studies, N = 389 vs (SMD, −0.31; 95% CI, −0.88 to 0.26; I 2 = 80%, P = .29, 3 studies, N = 333); Appendix S5). In the 6-and 12-month NMA, omega-3 was not significantly more effective at reducing APS compared to any other intervention.
| Cognitive remediation therapy
In the pairwise analyses, CRT interventions were not associated with a significant reduction in APS compared to computer games (MD, 1.60; 95% CI, −0.11 to 3.30; I 2 = 0%; P = .07, 3 studies, N = 170; Appendix S5). CRT studies were not assessed in the NMA because it was not connected to any treatment in the network.
| Integrated treatment in schizotypy
In the pairwise analyses, integrated treatments were not associated with a significant reduction in APS compared to standard care at long-term follow-up (2-3.5 years) in studies that targeted schizotypy participants only (MD, −0.28; 95% CI, −0.64 to 0.08; I 2 = 0%; P = .13, 2 studies, N = 116; Appendix S5). Schizotypy studies were not assessed in the NMA because it would violate the transitivity assumption.
| DISCUSSION
In summary, this systematic review compared the effects of CBT, family therapy, integrated psychological therapy, risperidone plus CBT, olanzapine, omega-3 and NMDAR modulators on reducing APS in CHR populations using both pairwise meta-analyse and NMA. First, pairwise metaanalyses revealed that CBT only demonstrated a trend towards reduction in APS compared to control treatments at 12-month follow-up. Risperidone plus CBT, NMDAR modulators, omega-3 and integrated treatments
were not significantly better than controls in pairwise analyses.
The second sentence of the above paragraph has been corrected.]
In the NMA, there were no significant results at both 6 and 12 months with all confidence intervals crossing the null line. However, there were some trends and effect sizes that may be of interest.
First, there was a trend favouring family therapy over the majority of interventions at both 6-month follow-up and a trend favouring CBT at 12 months, compared to the most other treatments.
Our CBT results are contrary to a previous meta-analysis which reported that CBT reduced APS at 12 months but not at 6 months or long-term follow-up (Hutton & Taylor, 2014) . However, in the current review, we did find a trend towards a significant reduction in APS at 12 months. This discrepancy in significance between reviews may be due to the presence of one additional CBT study which demonstrated no impact on APS compared to controls (Stain et al., 2016) Regardless, both this and the previous reviews demonstrated similar effect sizes for CBT.
Finally, there was a trend favouring CBT relative to other treatments at reducing APS in the 12-month NMA, albeit it was not significant.
Next, there was a trend favouring family therapy relative to other treatments at reducing APS in the NMA at 6 months, albeit it was not significant. Unfortunately, there was only 1 RCT examining family therapy in CHR youth and thus, the results of the NMA should be interpreted with caution until larger RCTs investigating the impact of family therapy in CHR samples emerge. However, 3 observational First, there is a lack of high-quality studies that examine the interventions in CHR and the impact these interventions have on APS.
Almost half of the RCTs failed to blind assessors from their respective treatment groups. Indeed, a lack of blinding of outcome assessments may have introduced important biases such as detection biases and performance biases which may have inflated the effect on APS in
RCTs that failed to blind assessors .
Second, we pooled a variety of APS scales using the SMD which may have important implications when interpreting the current results. The majority of studies employed the SOPS scale for measuring APS which includes unusual thought content, suspiciousness, grandiosity, perceptual abnormalities and disorganized communication. However, the PANSS was the second most commonly reported measure of APS which includes 2 additional positive symptoms (ie, excitement and hostility) and was developed to measure psychotic symptoms in patients with schizophrenia. Interestingly, although a consensus for negative symptoms exists no consensus has emerged for positive symptoms in schizophrenia (Kirkpatrick, Fenton, Carpenter, & Marder, 2006) . Thus, future considerations should be given to the strengths and weaknesses of available instruments for measuring APS and a collective agreement of what constitutes APS in CHR should be explored by CHR researchers.
Third, there was only 1 closed loop of evidence at both 6 and 12 months thus inconsistency can only statistically be examined between the nodes in these loops. A global test for inconsistency at 6 and 12 months revealed no significant evidence of inconsistency.
Other contributions of inconsistency were further examined using GRADE.
Fourth, another issue that arises from this NMA is that consistency of the indirect evidence cannot be adequately checked against direct evidence, especially given the limited amount of trials included in this NMA. Even though we found nothing statistically significant in terms of inconsistency in this NMA, these results should be interpreted with great caution because there is a limited amount of data.
Moreover, this NMA formed a complex star-shaped network and had many sparse connections, which elucidates the lack of direct evidence available in CHR studies. Indeed, the emergence of more trials in the future may change the results of this NMA entirely.
Fifth, in this NMA, several estimates have been based on little data and without direct evidence. Moreover, there were many large confidence intervals as can be seen in the NMA forest plots and thus the results may be based more on interference than on the actual impact of any particular intervention. Due to this lack of precision, the results should be interpreted cautiously. In addition, a lack of direct comparisons in a star-shaped network coupled with a limited amount trials could have inflated the chances of a type 2 error, which in this case may have led to the false-negative conclusion that a particular type of intervention had no effect. Indeed, as more trials emerge a single new trial could ultimately alter all of the results and conclusions made in this NMA. Thus, one should interpret the results of the NMA with great caution.
Sixth, risperidone plus CBT and omega-3 pairwise meta-analyses exhibited significant amounts of heterogeneity, but in meta-analyses of very few studies, the I 2 statistic may not be accurate (von Hippel, 2015) .
Directions for future research
The findings of the current systematic review and meta-analysis may inform several areas for future research. 
Conclusions
In conclusion, CBT demonstrated a trend at reducing APS at long-term follow-up compared to controls in pairwise analyses. No interventions were significantly more effective at reducing APS compared to all other interventions in the NMA. Family therapy although promising, require more clinical trials to determine a more precise and generalizable effect in CHR youth.
